Cited by 681

The DOI matches its Crossref record.

Exosomes from marrow stromal cells expressing miR-146b inhibit glioma growth

Katakowski, Mark, Buller, Ben, Zheng, Xuguang, Lu, Yong, Rogers, Thomas, Osobamiro, Oyinkansola, Shu, Wayne, Jiang, Feng, Chopp, Michael·2013·Cancer Letters

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.canlet.2013.02.019

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 24

  1. Bhaumik, 2008, Expression of microRNA-146 suppresses NF-kappaB activity with reduction of metastatic potential in breast cancer cells, Oncogene, 10.1038/onc.2008.171 · DOI
  2. Burgess, 2008, Epigenetic changes in gliomas, Cancer Biol. Ther., 7, 1326, 10.4161/cbt.7.9.6992 · DOI
  3. Chen, 2011, Enabling a robust scalable manufacturing process for therapeutic exosomes through oncogenic immortalization of human ESC-derived MSCs, J. Transl. Med., 9, 47, 10.1186/1479-5876-9-47 · DOI
  4. Croce, 2009, Causes and consequences of microRNA dysregulation in cancer, Nat. Rev. Genet., 10, 704, 10.1038/nrg2634 · DOI
  5. Dillman, 2004, Intracavitary placement of autologous lymphokine-activated killer (LAK) cells after resection of recurrent glioblastoma, J. Immunother., 27, 398, 10.1097/00002371-200409000-00009 · DOI
  6. Geletneky, 2012, Phase I/IIa study of intratumoral/intracerebral or intravenous/intracerebral administration of Parvovirus H-1 (ParvOryx) in patients with progressive primary or recurrent glioblastoma multiforme: ParvOryx01 protocol, BMC Cancer, 12, 99, 10.1186/1471-2407-12-99 · DOI
  7. Geraldo, 2012, MicroRNA miR-146b-5p regulates signal transduction of TGF-beta by repressing SMAD4 in thyroid cancer, Oncogene, 31, 1910, 10.1038/onc.2011.381 · DOI
  8. Guduric-Fuchs, 2012, Selective extracellular vesicle-mediated export of an overlapping set of microRNAs from multiple cell types, BMC Genomics, 13, 357, 10.1186/1471-2164-13-357 · DOI
  9. Hatanpaa, 2010, Epidermal growth factor receptor in glioma: signal transduction, neuropathology, imaging, and radioresistance, Neoplasia, 12, 675, 10.1593/neo.10688 · DOI
  10. He, 2011, Reduced expression of SMAD4 in gliomas correlates with progression and survival of patients, J. Exp. Clin. Cancer Res., 30, 70, 10.1186/1756-9966-30-70 · DOI
  11. Hu, 2012, Exosomal miRNAs: biological properties and therapeutic potential, Front. Genet., 3, 56, 10.3389/fgene.2012.00056 · DOI
  12. Katakowski, 2010, Functional microRNA is transferred between glioma cells, Cancer Res., 70, 8259, 10.1158/0008-5472.CAN-10-0604 · DOI
  13. Katakowski, 2010, MiR-146b-5p suppresses EGFR expression and reduces in vitro migration and invasion of glioma, Cancer Invest., 28, 1024, 10.3109/07357907.2010.512596 · DOI
  14. Lal, 2002, Mutant epidermal growth factor receptor up-regulates molecular effectors of tumor invasion, Cancer Res., 62, 3335
  15. Markert, 2009, Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM, Mol. Ther., 17, 199, 10.1038/mt.2008.228 · DOI
  16. Mellinghoff, 2011, Signal transduction inhibitors and antiangiogenic therapies for malignant glioma, Glia, 59, 10.1002/glia.21137 · DOI
  17. Oshiro, 2006, Evaluation of intratumoral administration of tumor necrosis factor-alpha in patients with malignant glioma, Anticancer Res., 26, 4027
  18. Rasheed, 1992, Loss of heterozygosity for 10q loci in human gliomas, Genes Chromosomes Cancer, 5, 75, 10.1002/gcc.2870050111 · DOI
  19. Riemenschneider, 2010, Molecular diagnostics of gliomas: state of the art, Acta Neuropathol., 120, 567, 10.1007/s00401-010-0736-4 · DOI
  20. Shao, 2011, PDGF induced microRNA alterations in cancer cells, Nucl. Acids Res., 39, 4035, 10.1093/nar/gkq1305 · DOI
  21. Silber, 2009, MicroRNAs in gliomas: small regulators of a big problem, Neuromol. Med., 11, 208, 10.1007/s12017-009-8087-9 · DOI
  22. Turner, 2010, The many roles of microRNAs in brain tumor biology, Neurosurg. Focus, 28, E3, 10.3171/2009.10.FOCUS09207 · DOI
  23. Xin, 2012, Exosome mediated transfer of miR-133b from multipotent mesenchymal stromal cells to neural cells contributes to neurite outgrowth, Stem Cells, 10.1002/stem.1129 · DOI
  24. Zheng, 2012, Studying a complex tumor: potential and pitfalls, Cancer J., 18, 107, 10.1097/PPO.0b013e3182431c57 · DOI

Cited by

Sorted by citations

See all 681

Metadata

Authors
Katakowski, M., Buller, B., Zheng, X., Lu, Y., Rogers, T., Osobamiro, O., Shu, W., Jiang, F., & Chopp, M.
Venue
Cancer Letters
Publisher
Elsevier BV
Published
2013-07
Volume
335
Issue
1
Pages
201-204
ISSN
0304-3835
Cited by
681
References
0
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review